Foreword

In the age of knowledge and technology, cancer is a disgrace on the face of humanity. Despite the fact that tremendous progress has been made in cancer therapy over the past 50 years, it remains a critical public health concern needing extensive research into new therapeutic strategies. Despite the availability of numerous anticancer drugs, issues such as multidrug resistance, diminished therapeutic efficacy, solubility, unwanted side effects, and poor bioavailability necessitate the development of novel anticancer therapies. Due to their exceptional pharmacological activity, specifically their anticancer properties, heterocyclic compounds have dominated medicinal chemistry for more than a century. Currently, the available chemical galaxy includes more than 100 million organic compounds, mainly related to a limited set of classes and types. At the same time, modern drug design trends require the development of synthetic approaches to equally and diversely fill the chemical space as a source of drug-like structures. These trends have affected heterocyclic chemistry as the main "supplier" of drug-like molecules (all top 10 brand name small molecule drugs contain heterocyclic moieties).

This book, which is named "Key Heterocyclic Cores for Smart Anticancer Drug-Design- Part II," offers a comprehensive analysis of several of the most interesting and contemporary hot topics in the research and development of cutting-edge cancer chemotherapeutics. This book is written with the intention of providing readers with a quick overview of the biological targets, structure-activity relationship (SAR), existing issues, and future prospects of heterocyclic-based anticancer drugs.

This book has piqued my interest tremendously, and I can't wait for it to be available in print as soon as possible. This book is useful as a resource for students, researchers, academicians, and medicinal chemists. The authors and Bentham publishers deserve praise for delivering timely and relevant information.